The issue of immunology in stem cell therapies: a pharmaceutical perspective.
Cautious approaches in the clinic are currently proposed, supported by relevant in vitro, in vivo and published data. Key to developing our understanding of the risks of immune rejection of stem cell based therapies will be the inclusion of immunological endpoints in clinical trials and the sharing of data. There is likely not a one-size-fits all strategy but one dependent on cell therapy, mode of action and disease indication.
Safety Assessment, GlaxoSmithKline R&D, Park Road, Ware, Herts., SG12 0DP, UK.
Richard
R
Haworth
Michaela
M
Sharpe
D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D007109:Immunity; D011173:Portraits as Topic; D013234:Stem Cells
MHC; MSC; clinical trials; hESC; iPS; immune privilege; immune rejection; immunodeficient; mice; stem cells